Wilkins Investment Counsel Inc. Sells 3,611 Shares of IQVIA Holdings Inc. $IQV

Wilkins Investment Counsel Inc. decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,363 shares of the medical research company’s stock after selling 3,611 shares during the period. IQVIA comprises approximately 2.2% of Wilkins Investment Counsel Inc.’s investment portfolio, making the stock its 17th biggest holding. Wilkins Investment Counsel Inc.’s holdings in IQVIA were worth $15,410,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in IQV. Vanguard Group Inc. boosted its holdings in IQVIA by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in IQVIA by 1.2% in the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the last quarter. Boston Partners purchased a new stake in IQVIA in the third quarter valued at $676,698,000. Artisan Partners Limited Partnership boosted its holdings in IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after purchasing an additional 367,204 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. Royal Bank Of Canada began coverage on shares of IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. Truist Financial lowered their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $174.00 to $213.00 in a report on Monday, March 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Buy” and an average target price of $226.63.

IQVIA Trading Down 0.4%

Shares of IQVIA stock opened at $157.73 on Friday. The firm has a market capitalization of $26.77 billion, a PE ratio of 20.07, a P/E/G ratio of 1.57 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The firm’s 50-day moving average price is $169.36 and its 200 day moving average price is $201.55. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.